Overview

• Mounjaro posted Rs 80 crore in September retail value sales, trailing only GSK’s Augmentin at Rs 85 crore.
• Monthly sales jumped 42% from August’s Rs 56 crore as demand strengthened and patients advanced to higher doses.
• Cumulative revenue since the March launch reached about Rs 233 crore, according to market data.
• A higher per‑patient cost, reported at roughly Rs 14,000 to Rs 27,000 a month, helped drive value despite lower volumes.
• A GST cut on medicines triggered short‑term distribution confusion in September, and rival Wegovy’s sales hovered near Rs 9 crore, Times of India reported.